Back to search results
NCT06280820

Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)

Enrolling by Invitation
Not specifiedAges 18+Observational
National Heart, Lung, and Blood Institute (NHLBI)
~2,000 participants
Updated 2026-09-18 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To study the association between multi-omics signatures with all-cause mortality
Measured over 10 years

Conditions

Heart Failure

Explore related trials

Heart Failure

NCT06280820

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • INOVA Fairfax Hospital

    Falls Church, Virginiano site contact published

  • University of Maryland School of Medicine

    Baltimore, Marylandno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Veronique L Roger, M.D. · PRINCIPAL_INVESTIGATOR · National Heart, Lung, and Blood Institute (NHLBI)

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Clinical diagnosis of "active" HF documented by a cardiology provider's note in the medical record. Active HF is the presence of signs or symptoms that are deemed to be related to heart failure, as documented in the participants' medical records.
Able and willing to undergo the consent process and provide consent
Willing to comply with required study activities
18 years of age or older

Exclusion

History of ventricular assist device
History of cardiac transplant
Living or residing outside of the geographic location designated for the study at the time of enrollment

What this trial measures

  • To study the association between multi-omics signatures with all-cause mortality10 years

    The heterogeneous HF syndrome encompasses different and poorly defined entities. Multi-omics can improve its characterization and the prediction of mortality, which remains high. All-cause mortality will be analyzed as the time from enrollment to all-cause death.